Management of heart failure – a challenge for the twenty-first century

Sammendrag

Introduction. Heart failure is a clinical syndrome caused by structural and functional defects in the myocardium resulting in impairment of ventricular filling or the ejection of blood. Over the past decades, the effectiveness of heart failure care has been markedly improved by the implementation of drug and device therapies with proven impact on mortality and morbidity but also by the development of advanced strategies for disease management in the outpatient setting.

The aim of our research was to highlight the social and economic impact of heart failure on the healthcare system.

Material and methods. A critical analysis of scientific articles published during 2018-2022 in PubMed, Medscape, Elsevier, and Hinari databases was done, using the following search words – heart failure, morbidity, disease, management, treatment, and prevention.

Results. Heart failure is considered an epidemic disease in the modern world affecting approximately 2% of the adult population and remaining the leading cause of morbidity and mortality globally. Heart failure is a highly symptomatic syndrome that affects 2–3% of the population in industrialized countries with a marked rise in those aged >65. It has been estimated that ∼15 million Europeans and 5.8 million US Americans suffer from heart failure. During the COVID-19 pandemic, socioeconomic deprivation, social isolation, and reduced physical activity triggered the enhancement in heart failure development and caused more severe complications. The most common cause of heart failure is reduced left ventricular myocardial function; however, dysfunction of the pericardium, myocardium, endocardium, heart valves, or main vessels alone or in combination is also associated with heart failure. The major goals of treatment in heart failure are to improve prognosis, reduce mortality, alleviate symptoms, and reduce morbidity by reversing or slowing cardiac and peripheral dysfunction. Standardized medical therapy has been successful in the early stages of heart failure. Advanced stages of heart failure require frequent hospitalization due to the severity of clinical symptoms or associated comorbid conditions, which require strict implementation of an appropriately individualized multidisciplinary approach and quality measures to reduce readmissions. Heart failure markedly affects the patient’s quality of life. Fear, anxiety, and depression are common. Epidemiologic studies suggest that, by focusing on a few clear prevention targets, it is possible to greatly reduce the suffering and economic costs resulting from heart failure.

Conclusions. Heart failure indeed is a complex disease and so far has been a major cause of morbidity and mortality in developing and developed countries. The prevention of heart failure is an urgent problem of public healthcare that requires national and global implications.

pdf (English)

|Utsikt: 127| |pdf (English) Nedlastinger: 48|


pdf (English)
##submission.license.cc.by4.footer##

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370